C-VGB3 

C-VGB3 is a selective vascular endothelial growth factor receptor 2 (VEGFR2) antagonist, which inhibits VEGFR2-mediated PI3K/AKT/mTOR and PLCγ/ERK1/2 signaling pathways. C-VGB3 binds to the extracellular domain of VEGFR2, blocking ligand-receptor interaction and inducing apoptosis in endothelial and tumor cells through both intrinsic (involving Bcl2 family and caspases) and extrinsic (death receptor-mediated) pathways. C-VGB3 is promising for research of angiogenesis-related cancers, such as breast cancer^[1][2].

1102.20

C₄₃H₆₇N₁₃O₁₇S₂

Glu-Cys-Arg-Pro-Pro-Asp-Asp-Gly-Leu-Cys (Disulfide bridge: Cys2-Cys10)

ECRPPDDGLC (Disulfide bridge: Cys2-Cys10)

O=C(N[C@@H](CSSC[C@@H](C(O)=O)NC1=O)C(N[C@@H](CCCNC(N)=N)C(N2[C@@H](CCC2)C(N3[C@@H](CCC3)C(N[C@@H](CC(O)=O)C(N[C@@H](CC(O)=O)C(NCC(N[C@H]1CC(C)C)=O)=O)=O)=O)=O)=O)=O)[C@H](CCC(O)=O)N

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Namjoo M, et al. A VEGFB-Based Peptidomimetic Inhibits VEGFR2-Mediated PI3K/Akt/mTOR and PLCγ/ERK Signaling and Elicits Apoptotic, Antiangiogenic, and Antitumor Activities. Pharmaceuticals (Basel). 2023 Jun 20;16(6):906.  [Content Brief]

  [2]. Sadremomtaz A, et al. Molecular docking, synthesis and biological evaluation of Vascular Endothelial Growth Factor (VEGF) B based peptide as antiangiogenic agent targeting the second domain of the Vascular Endothelial Growth Factor Receptor 1 (VEGFR1D2) for anticancer application. Signal Transduct Target Ther. 2020 Jun 5;5(1):76.  [Content Brief]